siponimod (Mayzent) Report issue

Small molecule Approved FDA Priority Review FDA
AACT ChEMBL DrugBank MeSH PubChem

Active Ingredient History

NOW
  • Now
Siponimod (BAF312) is a dual agonist at the sphingosine-1 phosphate receptors, S1PR1 and S1PR5. The S1P receptor is commonly found on the surface of specific cells residing in the central nervous system (CNS), that are responsible for causing CNS damage that drives loss of function in secondary progressive multiple sclerosis (SPMS). Siponimod (BAF312) enters the brain and by binding to these specific receptors, may prevent the activation of these harmful cells, helping to reduce the loss of physical and cognitive function associated with SPMS.   NCATS

Chemistry

  • SMILES: CCC1=C(CN2CC(C2)C(O)=O)C=CC(=C1)C(\C)=N\OCC3=CC(=C(C=C3)C4CCCCC4)C(F)(F)F
  • InChIKey: KIHYPELVXPAIDH-HNSNBQBZSA-N
  • Mol. Mass: 516.595
  • ALogP: 6.77
  • ChEMBL Molecules:
    siponimod  
    siponimod fumaric acid  
More Chemistry

Pharmacology

Drug Pricing (per unit)

Australia

$13.6481 - $58.4917

United States

$47.2636 - $253.2303
More Pricing Detail

Note: This drug pricing data is preliminary, incomplete, and may contain errors.

Alternative names

1-(4-(1-((e)-4-cyclohexyl-3-trifluoromethylbenzyloxyimino)-ethyl)-2-ethylbenzyl)-azetidine-3-carboxylic acid | baf312 | baf-312 | siponimod

Organizations (3)

Research & Development (3)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Marketing (1)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Indications (12)

Approved Indications (3)


 

Multiple Sclerosis (approved 2019)

Multiple Sclerosis, Chronic Progressive

Multiple Sclerosis, Relapsing-Remitting

Experimental Indications - Clinical Trial Phases 1-4 (12)


 

Dermatology (Phase 2)

Dermatomyositis (Phase 2)

Healthy Volunteers (Phase 1)

Hemorrhage (Phase 2)

Hemorrhagic Stroke (Phase 2)

Kidney Failure, Chronic (Phase 1)

Liver Diseases (Phase 1)

Lymphoma, Large B-Cell, Diffuse (Phase 3)

Multiple Sclerosis (Phase 3)

Multiple Sclerosis, Chronic Progressive (Phase 3)

Multiple Sclerosis, Relapsing-Remitting (Phase 2)

Polymyositis (Phase 2)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 15
  • # of Trial Organizations: 3

Trials by Phase

Trial Phase Start Date Organizations Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue